Review
doi: 10.3109/10428190109097706.
BCR-ABL fusion peptides and cytotoxic T cells in chronic myeloid leukaemia
Affiliations
- PMID: 11697642
- DOI: 10.3109/10428190109097706
Item in Clipboard
Review
BCR-ABL fusion peptides and cytotoxic T cells in chronic myeloid leukaemia
Leuk Lymphoma.
2001 Sep-Oct.
Abstract
The BCR-ABL gene that arises in chronic myeloid leukaemia (CML) is a neoantigen. Peptides derived from the BCR-ABL fusion junction may therefore be immunogenic, if appropriately presented to the immune system. This article reviews data demonstrating that certain junctional peptides will bind to HLA molecules, and that these peptides will elicit specific T-lymphocyte responses in vitro, in both normal subjects and in CML patients. The clinical relevance of these observations is discussed.
Similar articles
-
Peptides derived from the whole sequence of BCR-ABL bind to several class I molecules allowing specific induction of human cytotoxic T lymphocytes.Eur J Immunol. 1997 Aug;27(8):2066-72. doi: 10.1002/eji.1830270834. Eur J Immunol. 1997. PMID: 9295046
-
HLA class II-restricted antigen presentation of endogenous bcr-abl fusion protein by chronic myelogenous leukemia-derived dendritic cells to CD4(+) T lymphocytes.Blood. 2001 Sep 1;98(5):1498-505. doi: 10.1182/blood.v98.5.1498. Blood. 2001. PMID: 11520800
-
CD4(+) cytotoxic T-cell clones specific for bcr-abl b3a2 fusion peptide augment colony formation by chronic myelogenous leukemia cells in a b3a2-specific and HLA-DR-restricted manner.Blood. 1998 Nov 1;92(9):3355-61. Blood. 1998. PMID: 9787173
-
CML vaccines as a paradigm of the specific immunotherapy of cancer.Blood Rev. 2000 Jun;14(2):111-20. doi: 10.1054/blre.2000.0127. Blood Rev. 2000. PMID: 11012250 Review.
-
Chronic myeloid leukemia as an immunological target.Am J Hematol. 1997 Jan;54(1):61-7. doi: 10.1002/(sici)1096-8652(199701)54:1<61::aid-ajh9>3.0.co;2-2. Am J Hematol. 1997. PMID: 8980262 Review.
Cited by
-
Translational mini-review series on vaccines: Peptide vaccines for myeloid leukaemias.Clin Exp Immunol. 2007 May;148(2):189-98. doi: 10.1111/j.1365-2249.2007.03383.x. Clin Exp Immunol. 2007. PMID: 17437417 Free PMC article. Review.
-
Immunotherapeutic strategies in chronic myeloid leukemia.Curr Hematol Malig Rep. 2007 May;2(2):89-94. doi: 10.1007/s11899-007-0013-3. Curr Hematol Malig Rep. 2007. PMID: 20425356 Review.
-
Identification of new MHC-restriction elements for presentation of the p210(BCR-ABL) fusion region to human cytotoxic T lymphocytes.Cancer Immunol Immunother. 2003 Dec;52(12):761-70. doi: 10.1007/s00262-003-0415-6. Epub 2003 Oct 17. Cancer Immunol Immunother. 2003. PMID: 14564482 Free PMC article.
-
Vaccination strategies in lymphomas and leukaemias: recent progress.Drugs. 2011 Sep 10;71(13):1659-74. doi: 10.2165/11593270-000000000-00000. Drugs. 2011. PMID: 21902290 Review.
-
Generation of V α13/β21+T cell specific target CML cells by TCR gene transfer.Oncotarget. 2016 Dec 20;7(51):84246-84257. doi: 10.18632/oncotarget.12441. Oncotarget. 2016. PMID: 27713165 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous
